SCHEMBL6436081

SCHEMBL6436081

COc1ccc2c(c1)COc1c-2cc(C#N)c2cc(OC)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 3/20 0.38
ALOX15 P16050 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
USP2 O75604 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALDH1A1 P00352 3/20 0.37
GLA P06280 2/20 0.37
TDP1 Q9NUW8 3/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
ALOX12 P18054 1/20 0.37
MAPK1 P28482 2/20 0.37
CASP1 P29466 2/20 0.37
CASP7 P55210 2/20 0.37
RUNX1 Q01196 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437484 0.85 KCNJ1 (0.35) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL6439121 0.81 MAPT (0.39) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL6440958 0.79 SMN1; SMN2 (0.38) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL6440956 0.79 SMN1; SMN2 (0.38) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL3840410 0.78 ESR1 (0.41) CA1CA2CA4CA6PRF1
SCHEMBL6436723 0.77 MPO (0.36) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL6440485 0.76 HSP90AA1 (0.43) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL6436077 0.74 RXRA (0.46) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL6438595 0.74 MAOB (0.41) KDM4EMEN1KMT2AMAPTALOX15
SCHEMBL3195505 0.72 CYP17A1 (0.44) KDM4EMEN1KMT2AMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453820-B1 SUBSTITUTED 6H-DIBENZO[C,H]CHROMENES AS ESTROGENIC AGENTS WYETH CORP (US) 2005-06-01 EP disclosed
US-6723747-B2 ESTROGEN RECEPTOR MODULATORS USEFUL IN TREATING OR INHIBITING CONDITIONS, DISORDERS, OR DISEASE STATES AT LEAST PARTIALLY MEDIATED BY ESTROGEN DEFICIENCY OR EXCESS, OR WHICH MAY BE TREATED OR INHIBITED THROUGH USE OF ESTROGENIC AGENT WYETH 2004-04-20 US disclosed
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents WYETH 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents ESR2, ESR1, ESRRA KDM4E 638/4885MEN1 2298/4885KMT2A 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.